Evidence map›Paper›PMID 28869617›Full record

ArticleBone marrow transplantation2017

A phase 1 trial of

A Dispenzieri, A D'Souza, M A Gertz, K Laumann, G Wiseman, M Q Lacy, B LaPlant, F Buadi, S R Hayman, S K Kumar and 10 more

Registry-linked trialAbstract readClinical Trial, Phase IMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00477815 (A Phase I Trial of Zevalin Radioimmunotherapy With High-Dose Melphalan and Stem Cell Transplant for Multiple Myeloma), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00477815 phase1completednot on this map

A Phase I Trial of Zevalin Radioimmunotherapy With High-Dose Melphalan and Stem Cell Transplant for Multiple Myeloma

TypeinterventionalSponsorMayo ClinicRan2005 to 2018Enrolled30ConditionsMultiple Myeloma and Plasma Cell NeoplasmArmsrituximab, melphalan, Stem Cell, Sargramostim (GM-CSF), 90Y-Zevalin
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022
    Review
  3. Review
  4. Review
  5. Article
  6. Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors.International journal of molecular sciences · 2020
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

A DispenzieriDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
A D'SouzaHematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
M A GertzDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
K LaumannBiomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
G WisemanDivision of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA.
M Q LacyDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
B LaPlantBiomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
F BuadiDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
S R HaymanDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
S K KumarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
D DingliDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
W J HoganDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
S M AnsellDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
D A GastineauDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
D J InwardsDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
I N MicallefDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
L F PorrataDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
P B JohnstonDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
M R LitzowDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
T E WitzigDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Arizona · USMayo Clinic in Florida · USMedical College of Wisconsin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase 1 study (clinical trial NCT00477815) was conducted to determine the maximum tolerated dose (MTD) of yttrium-90 ibritumomab tiuxetan (

Indexed as

Hematopoietic Stem Cell TransplantationAdultAgedAntibodies, MonoclonalAutograftsDisease-Free SurvivalFemaleGranulocyte-Macrophage Colony-Stimulating FactorHumansMaleMaximum Tolerated DoseMelphalanMiddle AgedMultiple MyelomaRadioimmunotherapyRecombinant ProteinsAntibodies, MonoclonalGranulocyte-Macrophage Colony-Stimulating Factoribritumomab tiuxetanMelphalanRecombinant ProteinsRituximabsargramostim

Identifiers

PMID28869617
OpenAlexW2751560697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.